Human Oncology & Pathogenesis Program

The Andrew Intlekofer Lab

Research

Dr. Andrew Intlekofer
Andrew M. Intlekofer, MD, PhD

Andrew Intlekofer is an Assistant Member in the Human Oncology and Pathogenesis Program and an Attending Physician on the Lymphoma Service in the Department of Medicine. Dr. Intlekofer’s research investigates how deregulated metabolic pathways contribute to cancer development and how metabolic enzymes can be targeted for cancer treatment.

View Lab Overview

The Intlekofer Lab

Featured News

Andy Intlekofer
Big Ideas, Simple Experiments: At Work with Andrew Intlekofer
Physician-scientist Andrew Intlekofer studies the relationship between metabolism and cell differentiation.

Publications Highlights

Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein EM, Intlekofer AM. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discovery. 2018 Dec;8(12):1540-1547. doi: 10.1158/2159-8290.CD-18-0877.

Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, Famulare C, Correa FM, Takemoto N, Durani V, Liu H, Taylor J, Farnoud NR, Papaemmanuil E, Cross JR, Tallman MS, Arcila ME, Roshal M, Petsko GA, Wu B, Choe S, Konteatis ZD, Biller SA, Chodera JD, Thompson CB, Levine RL, Stein EM. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018 Jul;559(7712):125-129.

Intlekofer AM, Wang B, Liu H, Shah H, Carmona-Fontaine C, Rustenburg AS, Salah S, Gunner MR, Chodera JD, Cross JR, Thompson CB. L-2-hydroxyglutarate production arises from non-canonical enzyme function at acidic pH. Nature Chemical Biology. 2017 May;13(5):494-500. doi: 10.1038/nchembio.2307.

Intlekofer AM, Dematteo RG, Venneti S, Finley LWS, Lu C, Judkins AR, Rustenburg AS, Grinaway, PB, Chodera JD, Cross JR, Thompson CB. Hypoxia Induces Production of L-2-Hydroxyglutarate. Cell Metabolism. 2015 Aug 4; 22(2):304-11.

View All Publications

People

Dr. Andrew Intlekofer

Andrew M. Intlekofer, MD, PhD

  • Physician-scientist Andrew Intlekofer investigates why cancer cells depend on specific pathways of nutrient metabolism.
  • MD, PhD, University of Pennsylvania School of Medicine, PA.
View physician profile
Physician profile

Members

Zachary Epstein-Peterson
Zachary Epstein-Peterson
Research Fellow
Leo Fontenot
Research Fellow
Erick Gonzalez
Bridge Scholar
Shengqi Hou
Shengqi Hou
Research Fellow
GSK Student
Thomas F. McNamara
GSK Student
Jinsung Park
Jinsung Park
Research Fellow
Chione Sylvester
Chione Sylvester
Administrative Assistant
Naofumi Takemoto, PhD
Naofumi Takemoto
Senior Research Assistant
Christine Yu
Christine Yu
GSK Graduate Student
Sylvia Zohrabian
Sylvia Zohrabian
Graduate Student
Giscard Barbier
Giscard Barbier
Laboratory Administrator
Natalie Benjamin
Natalie Benjamin
Laboratory Admin
Fabian Correa
Fabian Correa
Senior Research Technician
Nicholas Klemen
Research Fellow
Maximilian Stahl
Maximilian Stahl
Clinical Fellow
Bo Wang, MS
Bo Wang
Senior Research Technician

Achievements

  • Damon Runyon Clinical Investigator Award (2018)
  • ASCI Young Physician-Scientist Award (2018)
  • Burroughs Wellcome Fund Career Award for Medical Scientists (2016)
  • NCI K08 Mentored Clinical Scientist Research Career Development Award (2016)
  • Steven Greenberg Lymphoma Research Award (MSKCC) (2016)
  • Leukemia & Lymphoma Society Special Fellow Award (2015)
  • Conquer Cancer Foundation of ASCO Young Investigator Award (2014)
  • Stuart Mudd Award for Excellence and Creativity in Microbiology (UPenn) (2009)
  • Saul Winegrad Award for Outstanding Ph.D. Dissertation (UPenn) (2008)
  • Balduin Lucke Prize for Research in Experimental Medicine and Biology (UPenn) (2006)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Andrew M. Intlekofer discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures